Atara Biotherapeutics price target raised to $21 from $13 at Canaccord

Canaccord analyst John Newman raised the firm’s price target on Atara Biotherapeutics (ATRA) to $21 from $13 and keeps a Buy rating on the shares. The firm said its target increase is based on its expectations for positive ATA3219 data in NHL and Lupus in early 2025.